secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2021-09-08T23:59:59+00:00
Accession:  0001558370-21-012312
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine appoints Emma Reeve to Board as independent director
--------------------------------------------------------------------

- Emma Reeve appointed independent Class III director effective September 3, 2021, until 2022 annual meeting.
- She will serve on the Audit Committee and qualifies as an audit committee financial expert.
- Ms. Reeve was SVP/CFO of Constellation Pharmaceuticals until its acquisition in July 2021.
- Compensation includes $40,000 annual board retainer, $7,500 audit committee retainer, and option for 13,736 shares vesting over three years.
- She also serves on the board of PTC Therapeutics since December 2018.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000155837021012312/0001558370-21-012312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000155837021012312/edit-20210903x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-012312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer